Dashboard
Manage Tickers

GOSS


()    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

hc-wainwright--co-reiterates-buy-on-gossamer-bio-maintains-10-price-target
HC Wainwright & Co. Reiterates Buy on Goss...
05/20/2024 15:10:24

HC Wainwright & Co. analyst Patrick Trucchio reiterates Gossamer Bio (NASDAQ:GOSS) with a Buy and maintains $10 price ta...

gossamer-bio-provides-updated-seralutinib-torrey-open-label-extension-data-at-the-american-thoracic-society-2024-international-conference-which-takes-place-may-17-22
Gossamer Bio Provides Updated Seralutinib ...
05/14/2024 20:15:56

Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization o...

12-health-care-stocks-moving-in-mondays-after-market-session
12 Health Care Stocks Moving In Monday's A...
05/13/2024 20:31:07

wedbush-reiterates-outperform-on-gossamer-bio-maintains-4-price-target
Wedbush Reiterates Outperform on Gossamer ...
05/08/2024 14:19:14

Wedbush analyst Laura Chico reiterates Gossamer Bio (NASDAQ:GOSS) with a Outperform and maintains $4 price target.

gossamer-bio-q1-eps-019-misses-018-estimate
Gossamer Bio Q1 EPS $(0.19) Misses $(0.18)...
05/07/2024 20:48:04

Gossamer Bio (NASDAQ:GOSS) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $(0.18...

gossamer-bio-collaborates-with-italian-drugmaker-chiesi-to-advance-lung-health-solutions-worldwide
Gossamer Bio Collaborates With Italian Dru...
05/06/2024 17:17:19

Gossamer Bio partners with Chiesi Farmaceutici to develop and market seralutinib globally, targeting pulmonary arterial hyperte...

hc-wainwright--co-reiterates-buy-on-gossamer-bio-maintains-10-price-target
HC Wainwright & Co. Reiterates Buy on Goss...
05/06/2024 16:16:31

HC Wainwright & Co. analyst Patrick Trucchio reiterates Gossamer Bio (NASDAQ:GOSS) with a Buy and maintains $10 price ta...

watching-gossamer-bio-traders-circulate-unconfirmed-analyst-comments-suggesting-partnership-with-chiesi-group-is-a-major-win-for-seralutinib-development-partnership-further-increases-pos-for-the-development-of-seralutinib-as-a-best-in-class-therapeutic-reiterates-buy-rating-and-15-pt
Watching Gossamer Bio; Traders Circulate U...
05/06/2024 14:40:28

trading-halt-halt-status-updated-at-75500-am-et-quotation-resumption-news-and-resumption-times
Trading Halt: Halt status updated at 7:55:...
05/06/2024 11:55:07

gossamer-bio-secures-160m-partnership-with-chiesi-group-to-accelerate-development-of-pulmonary-hypertension-treatment-486m-potential-for-seralutinib-collaboration
Gossamer Bio Secures $160M Partnership wit...
05/06/2024 11:37:40

Gossamer Bio, Inc. ("Gossamer") (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on the development an...

trading-halt-halted-at-72500-am-et---trading-halt-halt-news-pending
Trading Halt: Halted at 7:25:00 a.m. ET - ...
05/06/2024 11:25:04

gossamer-bio-published-torrey-phase-2-results-in-lancet-respiratory-medicine
Gossamer Bio Published TORREY Phase 2 Resu...
05/03/2024 12:02:56

12-health-care-stocks-moving-in-thursdays-after-market-session
12 Health Care Stocks Moving In Thursday's...
04/25/2024 20:32:50

12-health-care-stocks-moving-in-fridays-after-market-session
12 Health Care Stocks Moving In Friday's A...
04/05/2024 20:31:09

wedbush-assumes-gossamer-bio-at-outperform-announces-price-target-of-4
Wedbush Assumes Gossamer Bio at Outperform...
04/05/2024 08:57:25

Wedbush analyst Laura Chico assumes Gossamer Bio (NASDAQ:GOSS) with a Outperform rating and announces Price Target of $4.

piper-sandler-maintains-overweight-on-gossamer-bio-maintains-15-price-target
Piper Sandler Maintains Overweight on Goss...
03/27/2024 16:43:02

Piper Sandler analyst Yasmeen Rahimi maintains Gossamer Bio (NASDAQ:GOSS) with a Overweight and maintains $15 price target.

goldman-sachs-maintains-buy-rating-for-gossamer-bio-heres-what-you-need-to-know
Goldman Sachs Maintains Buy Rating for Gos...
03/06/2024 17:00:20

goldman-sachs-maintains-buy-on-gossamer-bio-lowers-price-target-to-8
Goldman Sachs Maintains Buy on Gossamer Bi...
03/06/2024 16:36:33

Goldman Sachs analyst Paul Choi maintains Gossamer Bio (NASDAQ:GOSS) with a Buy and lowers the price target from $9 to $8.

wedbush-reiterates-outperform-on-gossamer-bio-maintains-6-price-target
Wedbush Reiterates Outperform on Gossamer ...
03/06/2024 16:11:39

Wedbush analyst Andreas Argyrides reiterates Gossamer Bio (NASDAQ:GOSS) with a Outperform and maintains $6 price target.

hc-wainwright--co-reiterates-buy-on-gossamer-bio-maintains-10-price-target
HC Wainwright & Co. Reiterates Buy on Goss...
03/06/2024 13:44:27

HC Wainwright & Co. analyst Patrick Trucchio reiterates Gossamer Bio (NASDAQ:GOSS) with a Buy and maintains $10 price ta...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION